Pharmaceutical Research

, 28:2261

Targeted Delivery to Neuroblastoma of Novel siRNA-anti-GD2-liposomes Prepared by Dual Asymmetric Centrifugation and Sterol-Based Post-Insertion Method

  • Joanna E. Adrian
  • Alexander Wolf
  • Annette Steinbach
  • Jochen Rössler
  • Regine Süss
Research Paper

ABSTRACT

Purpose

To optimise and simplify preparation of targeted liposomes for efficient siRNA delivery to neuroblastoma, the most common solid tumour in early childhood.

Methods

Liposomes containing siRNA were prepared by combining the novel dual asymmetric centrifugation (DAC) method and the recently optimised sterol-based post-insertion technique (SPIT) to couple anti-GD2 antibody for selective interaction with neuroblastoma cells. Cultured human neuroblastoma cell lines were used to evaluate the efficiency of siRNA delivery.

Results

The size of liposomes prepared by DAC ranged from 190 to 240 nm; siRNA encapsulation efficiency was up to 50%. An average of 70 and 100 molecules of anti-GD2 antibody per particle were coupled. A significant association of liposomes with neuroblastoma cells as well as effective siRNA delivery was observed only when anti-GD2 antibody was coupled. Preliminary data suggest delivery of siRNA using anti-GD2-liposomes occurs via GD2-mediated endocytosis. Vascular endothelial growth factor A (VEGF-A) was down-regulated using siRNA delivered by anti-GD2-liposomes.

Conclusions

DAC and SPIT allow for the straightforward preparation of liposomes for the targeted delivery of siRNA. Anti-GD2-liposomes thus produced can serve as versatile carriers of siRNA to neuroblastoma cells.

KEY WORDS

dual asymmetric centrifugation GD2 antibody neuroblastoma post-insertion technique siRNA delivery 

ABBREVIATIONS

Ab

antibody

Chol

cholesterol

cryo-TEM

cryo-transmission electron microscope

DAC

dual asymmetric centrifugation

DDAB

dimethyldioctadecylammonium (bromide salt)

DSPE-PEG2000

2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol)-2000]

FCS

fetal calf serum

GD2

disialoganglioside

HN buffer

HEPES/NaCl buffer

HSPC

hydrogenated soybean phosphatidylcholine

L

liposomes

PBS

phosphate buffered saline

POPC

1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine

Rhd-PE

rhodamine B 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine triethylammonium salt

siRNA

short interfering RNA

SPIT

sterol-based post-insertion technique

TL

total lipid

VEGF-A

vascular endothelial growth factor A

REFERENCES

  1. 1.
    Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411:494–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Tiemannand K, Rossi JJ. RNAi-based therapeutics-current status, challenges and prospects. EMBO Mol Med. 2009;1:142–51.CrossRefGoogle Scholar
  3. 3.
    de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov. 2007;6:443–53.PubMedCrossRefGoogle Scholar
  4. 4.
    Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN, et al. RNAi-mediated gene silencing in non-human primates. Nature. 2006;441:111–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res. 2008;68:9078–86.PubMedCrossRefGoogle Scholar
  6. 6.
    Peer D, Park EJ, Morishita Y, Carman CV, Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science. 2008;319:627–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005;4:145–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Hirsch M, Ziroli V, Helm M, Massing U. Preparation of small amounts of sterile siRNA-liposomes with high entrapping efficiency by dual asymmetric centrifugation (DAC). J Control Release. 2009;135:80–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Gurney JG, Ross JA, Wall DA, Bleyer WA, Severson RK, Robison LL. Infant cancer in the U.S.: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol. 1997;19:428–32.PubMedCrossRefGoogle Scholar
  10. 10.
    Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–16.PubMedCrossRefGoogle Scholar
  11. 11.
    Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther. 2006;13:464–77.PubMedCrossRefGoogle Scholar
  12. 12.
    Gantert M, Lewrick F, Adrian JE, Rossler J, Steenpass T, Schubert R, et al. Receptor-specific targeting with liposomes in vitro based on sterol-PEG(1300) anchors. Pharm Res. 2009;26:529–38.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhang S, Cordon-Cardo C, Zhang HS, Reuter VE, Adluri S, Hamilton WB, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer. 1997;73:42–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Hettmer S, Ladisch S, Kaucic K. Low complex ganglioside expression characterizes human neuroblastoma cell lines. Cancer Lett. 2005;225:141–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Kazarian T, Jabbar AA, Wen FQ, Patel DA, Valentino LA. Gangliosides regulate tumor cell adhesion to collagen. Clin Exp Metastasis. 2003;20:311–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Navid F, Armstrong M, Barfield RC. Immune therapies for neuroblastoma. Cancer Biol Ther. 2009;8:874–82.PubMedCrossRefGoogle Scholar
  17. 17.
    Filleur S, Courtin A, Ait-Si-Ali S, Guglielmi J, Merle C, Harel-Bellan A, et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res. 2003;63:3919–22.PubMedGoogle Scholar
  18. 18.
    Bartlett GR. Phosphorus assay in column chromatography. J Biol Chem. 1959;234:466–8.PubMedGoogle Scholar
  19. 19.
    Adrian JE, Morselt HW, Suss R, Barnert S, Kok JW, Asgeirsdottir SA, et al. Targeted SAINT-O-Somes for improved intracellular delivery of siRNA and cytotoxic drugs into endothelial cells. J Control Release. 2010;144:341–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Adrian JE, Kamps JA, Scherphof GL, Meijer DK, van Loenen-Weemaes AM, Reker-Smit C, et al. A novel lipid-based drug carrier targeted to the non-parenchymal cells, including hepatic stellate cells, in the fibrotic livers of bile duct ligated rats. Biochim Biophys Acta. 2007;1768:1430–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Tettamanti G. Ganglioside/glycosphingolipid turnover: new concepts. Glycoconj J. 2004;20:301–17.PubMedCrossRefGoogle Scholar
  22. 22.
    Kowanetzand M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12:5018–22.CrossRefGoogle Scholar
  23. 23.
    Jakovljevic G, Culic S, Stepan J, Bonevski A, Seiwerth S. Vascular endothelial growth factor in children with neuroblastoma: a retrospective analysis. J Exp Clin Cancer Res. 2009;28:143.PubMedCrossRefGoogle Scholar
  24. 24.
    Massing U, Cicko S, Ziroli V. Dual asymmetric centrifugation (DAC)–a new technique for liposome preparation. J Control Release. 2008;125:16–24.PubMedCrossRefGoogle Scholar
  25. 25.
    Ivanov AI. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods Mol Biol. 2008;440:15–33.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Joanna E. Adrian
    • 1
    • 2
  • Alexander Wolf
    • 2
  • Annette Steinbach
    • 1
  • Jochen Rössler
    • 2
  • Regine Süss
    • 1
  1. 1.Department of Pharmaceutical Technology & BiopharmacyAlbert-Ludwigs UniversityFreiburgGermany
  2. 2.Center of Paediatrics & Adolescent Medicine Division of Paediatric Haematology & OncologyUniversity Medical Center FreiburgFreiburgGermany

Personalised recommendations